A randomized controlled trial analyzing nonthermal atmospheric plasma for the treatment of verruca vulgaris in pediatric patients - 18/12/24
Abstract |
Background |
Verruca vulgaris (VV) is a common viral disease in children. Treatment options are often not well tolerated in children due to pain or adverse effect risk. Nonthermal atmospheric plasma (NTAP), which generates reactive oxygen/nitrogen species, is well tolerated and without adverse effects.
Objective |
Determine efficacy of NTAP as compared to standard of care (SOC) therapy for VV in children.
Methods |
This prospective open-label study randomized lesions 1:1 to receive NTAP or SOC (cryotherapy). Patients were treated at 4-week intervals for a maximum of 3 treatments. They were evaluated 4 weeks postfinal treatment for sustained response. Primary outcome was lesion response.
Results |
One hundred twelve VV lesions in 14 patients were enrolled. Patients were mostly White (92.9%) males (71.4%) with mean age of 9.5 [±2.5] years. Responses of SOC- and NTAP-treated lesions, respectively, included no response (5.4%, 7.1%); partial response (33.9%, 41.1%); and complete resolution (60.7%, 51.8%; P value = .679). Patients were more likely to report pain in SOC lesions post-treatment (P value <.001). No significant adverse events (AEs) occurred.
Limitations |
Limitations include single-site, maximum of 3 treatments, and short post-treatment follow-up.
Conclusion |
NTAP is an efficacious, safe intervention for treatment of VV in children.
Le texte complet de cet article est disponible en PDF.Key words : cryotherapy, pediatric dermatology, plasma, randomized controlled study, RCT, treatment, warts
Abbreviations used : AE, NTAP, SOC, VV
Plan
Funding sources: None. |
|
Patient consent: Consent for the publication of recognizable patient photographs or other identifiable material was obtained by the authors and included at the time of article submission to the journal stating that all patients gave consent with the understanding that this information may be publicly available. |
|
IRB approval status: Reviewed and approved by Western IRB; approval #106689. |
Vol 92 - N° 1
P. 46-50 - janvier 2025 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?